Tirzepatide 60mg Research Peptide
Tirzepatide is the first FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro/Zepbound, Eli Lilly), representing a landmark in incretin-based metabolic research. This 60mg bulk vial provides the largest single-vial quantity of research-grade tirzepatide at ≥99% purity, suitable for extended research protocols or multi-model studies. HPLC and MS/MS verified per batch with third-party COA available.
Research Background
Tirzepatide’s dual GIPR/GLP-1R mechanism produces superior metabolic outcomes compared to selective GLP-1 agonists across multiple clinical trial programs. SURMOUNT-1 demonstrated 22.5% mean weight reduction at 72 weeks at the highest dose — a benchmark that has driven intense research interest in GIP receptor biology and dual/triple incretin agonism. As the immediately preceding compound to retatrutide (triple agonist) in the incretin agonist development progression, tirzepatide provides an essential research comparator for studying the added contribution of GCGR co-activation to metabolic outcomes.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 60mg per vial
- Storage: −20°C, protected from light
- CAS Number: 2023788-19-2
- Molecular Weight: 4813.5 Da
Certificate of Analysis
Third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
